Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

NCT01910389 is registered in ClinicalTrials.gov with Carelon Research as lead sponsor.

NCT NCT01910389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01910389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
Lead sponsor
Carelon Research
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2013
Completion date
February 28, 2014
Enrollment
23 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, pulmonary hypertension